Burkitt lymphoma (BL) is a malignant disease, which is frequently found in areas with holoendemic Plasmodium falciparum malaria. We have previously found that the VAR2CSA protein is present on malaria-infected erythrocytes and facilitates a highly specific binding to the placenta. ofCS is absent in other non-malignant tissues and thus VAR2CSA generally facilitates parasite sequestration and accumulation in pregnant women. In this study, we show that the specific receptor for VAR2CSA, the oncofetal chondroitin sulfate (ofCS), is likewise present in BL tissue and cell lines. We therefore explored whether ofCS in BL could act as anchor site for VAR2CSA-expressing infected erythrocytes. In contrast to the placenta, we found no evidence of in vivo sequestering of infected erythrocytes in the BL tissue. Furthermore, we found VAR2CSA-specific antibody titers in children with endemic BL to be lower than in control children from the same malaria endemic region. The abundant presence of ofCS in BL tissue and the absence of ofCS in non-malignant tissue encouraged us to examine whether recombinant VAR2CSA could be used to target BL. We confirmed the binding of VAR2CSA to BL-derived cells and showed that a VAR2CSA drug conjugate efficiently killed the BL-derived cell lines in vitro. These results identify ofCS as a novel therapeutic BL target and highlight how VAR2CSA could be used as a tool for the discovery of novel approaches for directing BL therapy.
Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma, which affects children between the ages of 0 and 15 years. 1, 2 The disease is associated with Epstein-Barr virus (EBV) infection of the malignant cells and is most frequently found in areas with holoendemic malaria. Most people become infected with EBV during their lifetime without any apparent consequences. 3 However, latent EBV-infected B-cells can be reactivated in settings of congenital or acquired immunosuppression leading to the establishment and polyclonal outgrowth that result in BL. [4] [5] [6] [7] [8] The high BL incidence in areas with holoendemic Plasmodium falciparum suggests a possible link between malaria infection and BL in equatorial Africa, where the disease is termed endemic BL (eBL). [9] [10] [11] Epidemiological studies have suggested that the risk of eBL is highest during childhood when exposure to malaria peaks as measured by antibody levels and that the risk diminishes as children acquire antimalarial immunity and thereby gain immunological control of the blood stage parasites. [12] [13] [14] [15] We have recently shown that the placental syncytiotrophoblast and the majority of all cancers produce a distinct oncofetal type of chondroitin sulfate (ofCS), which is absent from normal cells and tissues. 16 CS consists of long glycosaminoglycan (GAG) chains that can be attached to a diverse panel of protein cores, which together are termed chondroitin sulfate proteoglycans (CSPGs). 17 The CS chains bind several ligands and receptors, and CSPGs thereby act as major factors in tumor growth and invasion. [18] [19] [20] [21] [22] [23] EBV-positive BLderived cell lines have recently been shown to express a broad repertoire of CSPGs. 24 However, the functional significance of CSPG expression in BL is still largely unknown.
In the placenta, P. falciparum malaria-infected erythrocytes exploit the presence of ofCS to anchor themselves to the endothelial lining thereby avoiding splenic clearance during blood circulation. 25 The accumulation of malaria parasites in the placenta causes pregnancy-associated malaria with severe consequences for the woman and the developing fetus. 26 Placental cytoadhesion of infected erythrocytes to ofCS is mediated by the VAR2CSA protein expressed by malaria parasites on the surface of infected erythrocytes. 27 Protection against pregnancy-associated malaria is acquired as a function of parity and correlated to elevated levels of anti-VAR2CSA IgG. [28] [29] [30] [31] Despite the highly specific adhesion in the placenta, studies have shown that naturally acquired antibodies against VAR2CSA are not restricted to pregnant women as low titers can also be detected in a small subset of men and children. [32] [33] [34] Thus, low levels of VAR2CSA-espressing parasites may be present in the bloodstream of malaria-infected children but rapidly cleared by the spleen, as they cannot adhere to the vascular endothelial lining.
In the light of our novel finding that most cancers produce the ofCS to which VAR2CSA specifically adheres, we initially hypothesized that the presence of BL may provide a niche for the accumulation of VAR2CSA-expressing parasites in malaria-infected non-pregnant individuals. In this study, we show that BL cell lines as well as patient biopsies present the specific ofCS recognized by the recombinant VAR2CSA protein (rVAR2). We further evaluated if VAR2CSA-expressing infected erythrocytes could bind to the tumor site, and finally, whether an rVAR2-drug conjugate could kill ofCS-expressing BL-derived cells in vitro. These data highlight how the molecular biology of malaria can potentially be used in the development of novel tools for the treatment of BL.
Materials and Methods

Immunohistochemistry of BL tissue for placenta-like chondroitin sulfate
Formalin-fixed and paraffin-embedded (FFPE) BL tumor tissues (n 5 16) obtained in the EMBLEM Study (http:// emblem.cancer.gov/) were retrieved in tissue microarray format (TMA) to study rVAR2 binding and sequestration of infected erythrocytes in BL tissue.
Four microns sectioned paraffin-embedded 1 mm tissue cores were stained with 500 pM recombinant DBL1-ID2a (rVAR2) without antigen retrieval. 35 After a secondary incubation with 7003 diluted monoclonal anti-V5 mouse antibody followed by an incubation with UMAP anti-mouse HRP, rVAR2 binding was detected by staining with the ChromoMap DAB Kit on a Ventana Discovery platform. Samples were counterstained with hematoxylin. Additional paraffin-embedded tissue samples were stained with hematoxylin and eosin (H&E) and Giemsa and evaluated for the presence of P. falciparum-infected erythrocytes by light microscopy.
Immunofluorescence staining of ofCS in BL
For immunofluorescence staining, confirmed BL tissues from the SEER Residual Tissue Repository from the United States was used. FFPE tissue was deparafinized and rehydrated with a series of xylene and ethanol solutions. After blocking, the tissue was incubated with 50 nM rVAR2, followed by What's new? Co-infection by Epstein-Barr virus and the malarial parasite Plasmodium falciparum is a suspected etiological factor in endemic Burkitt lymphoma (BL). Meanwhile, oncofetal chondroitin sulfate (ofCS), a binding anchor for VAR2CSA-expressing Plasmodium-infected erythrocytes in the placenta, is expressed in diverse types of tumors. This study shows that ofCS is also expressed in BL tissue, though it does not serve a role in the sequestration of infected erythrocytes. In vitro, BL cells were successfully targeted and killed by a malaria-derived VAR2CSA drug conjugate, suggesting that ofCS expression could be leveraged to deliver a toxic payload to BL tissue.
incubation with anti-V5-FITC antibody (Invitrogen). The specificity of rVAR2 binding was tested by outcompeting protein binding with 400 lg/ml CSA (Sigma). An additional specificity control was performed by treating the tissue with 0.5 U/ml chondroitinase ABC (ChABC, Sigma) for 1 hr at 378C, before blocking. Samples were counterstained with DAPI.
Imaging was performed on a Nikon C1 confocal microscope with a 603 oil objective. Each image is a composite of the following channels: blue (nuclei), green (ofCS) and red (auto-fluorescence of the tissue).
In vitro cultures
The P. falciparum FCR3 parasites were cultured in RPMI 1640 (Sigma) supplemented with 0.125 lg/ml Albumax II (Invitrogen), 5% hematocrit of human blood (Group 01) and 2% normal human serum, as previously described. 36 Infected erythrocytes were maintained in a mixture of 2% O 2 and 5% CO 2 in nitrogen at 378C. VAR2CSA expression was ensured by panning on BeWo cells 37 and genotype was validated using a nested polymerase chain reaction (PCR) with GLURP and MSP-2 primers.
The sporadic BL-derived cell lines 38 were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin and 100 lg/ mL streptomycin. Cell lines were passaged to a cell density of 2 3 10 5 /ml on a regular basis and maintained at 5% CO 2 at 378C.
BL cells and FCR3 parasites were regularly tested for mycoplasma and shown free of contamination (Lonza).
Flow cytometry of BL-derived cell lines
Binding of rVAR2 to sporadic BL-derived cell lines was evaluated using 2 3 10 6 cells/ml incubated with his-tagged 400-1.56 nM recombinant DBL1-ID2a (rVAR2) in PBS containing 2% FBS for 30 min at 48C. After a secondary incubation using a 500 times diluted anti-penta his alexa fluor 488 antibody (Qiagen), binding was analyzed using an FC500 flow cytometer (Beckmann Coulter). To test specificity of rVAR2 binding to the BL-derived cell lines, cells were stained with rVAR2 (200 nM) in the presence of increasing amounts (twofold dilution, from 200-0 lg/ml) of CSA (Sigma) and HS (Sigma). After a secondary incubation using a 500 times diluted anti-V5-FITC (Invitrogen), binding was analyzed using an FC500 flow cytometer (Beckmann Coulter). An additional specificity control was done by preincubating the cells with 0.5 U/ml ChAC (Sigma) for 1 hr at 378C. Finally, a domain of the VAR2CSA protein known not to be involved in the binding (rDBL4) was also used as a control.
Reverse phase-HPLC (RP-HPLC)
Five million cells were frozen in liquid nitrogen, and prepared for HPLC analysis. Samples were digested with Pronase and Benzonase in two separate consecutive overnight incubations at 378C. After digestion, the samples were loaded onto a dietilaminoetil (DEAE) column and eluted with 20 mM NaOAc, 1 M NaCl, pH 5.0. The eluted samples were concentrated by speed-vacuum and precipitated with ethanol saturated with NaOAc (1:3, v:v) overnight at 48C. Dried samples were treated with 40 mU of ChABC overnight at 378C and freeze-dried for 2 hrs. For AMAC labeling, 5 ll of 0.1 M AMAC were added to the samples for 15 min at room temperature. After this incubation, 5 ll of 1 M NaCNBH 3 was added for 3 hrs at 458C. The samples were then freeze-dried overnight, precipitated with acetone and injected onto the RP-HPLC.
Binding of infected erythrocytes to BL cells FCR3 parasites were enriched for late trophozoite and schizont stages in a strong magnetic field (Miltenyi Biotec). 5 3 10 6 infected erythrocytes and 1 3 10 6 BL cells were incubated in complement medium for 2 hrs at room temperature. Smears of the suspension were prepared on glass slides and fixed with 100% methanol. Samples were stained with 10% Giemsa stain and analyzed using a Nikon TE 2000-E confocal microscope with 603 oil immersion objective lens (DIC).
Study population
Residual serum was obtained from the historical BL studies conducted by investigators at the National Cancer Institute in Ghana. 39, 40 Briefly, children (2-15 years) with histologically or cytologically confirmed BL were enrolled from Korle-Bu Teaching Hospital, Accra, Ghana from 1965 through 1994. The cases were mostly from southern areas of Ghana, where malaria transmission intensity was moderate to high. 41 The controls were apparently healthy children of a similar age and sex to the cases enrolled from the same neighborhood, except for a few children referred to the Korle-Bu Teaching Hospital with suspected eBL but found to have benign or a nonlymphoid malignancy. 42 These controls were representative of the cases in terms of referral patterns. Verbal consent (or assent for children aged 8 years or older) was obtained prior to enrolment. Age, sex and date of enrolment were recorded on structured forms. Malaria status was evaluated by light microscopy at the time of the study and children who were positive were treated. A pretreatment venous blood sample was drawn and separated into aliquots, which were stored at 2708C at the U.S. National Cancer Institute repository until testing. Previously unthawed samples or aliquots of samples that were thawed once only were used in this study.
Ethical approval for the current study was obtained from the Office of Human Subject Research at the US National Institutes of Health. No identifying subject data were used in this study. Sera from P. falciparum exposed individuals from Tanzania (20 children and 21 multigravidae women) and Danish controls na€ ıve to malaria (n 5 9) were included as technical controls. Antibodies to VAR2CSA antigens were measured using two methods: an enzyme-linked immunosorbent assay (ELISA) and flow cytometry.
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ELISA
Nunc MaxiSorpH plates were coated overnight at 48C with 1 lg/ml recombinant full-length VAR2CSA, produced in baculovirus-transfected insect cells as previously described. 43 Following 1 hr incubation in blocking buffer, serum samples were added to the wells in duplicates and incubated for 1 hr at room temperature. After washing the plate, 3000 times diluted horseradish peroxidase (HRP)-conjugated polyclonal rabbit anti-human IgG (DAKO, Denmark) was added to the wells and incubated for 1 hr. After incubation with ophenylenediamine substrate, the reaction was stopped by 2.5 M H 2 SO 4 and the binding was measured at 490 nm using an ELISA plate reader (VersaMax Molecular Devices).
Flow cytometry on infected erythrocytes
The reactivity of the test serum with infected erythrocytes was measured using flow cytometry with VAR2CSA-expressing FCR3 parasites enriched for late trophozoite and schizont stages in a strong magnetic field (Miltenyi Biotec). 2 3 10 5 infected erythrocytes were stained with ethidium bromide (Invitrogen) and incubated with 20 times diluted serum, which had been depleted for unspecific binding by preincubation with uninfected erythrocytes. After a secondary incubation using a 200 times dilution of goat anti-human IgG FITC antibody (FI3000, Vector), binding was analyzed using an FC500 flow cytometer (Beckmann Coulter).
Statistical methods
Laboratory staff were blinded to the status (case or control) of the samples to minimize bias, and 27% of samples (n 5 59) were embedded as replicate vials within the same and also in different test plates to measure within-and between-plate assay reproducibility (Supporting Information, Fig. 1 ). Within-and between-plate coefficients of variation (CVs)-calculated by dividing assay mean by the assay standard deviation of replicate samples-were used to evaluate reliability of IgG assays. Assay results with CVs equal or higher than 30% failed and were excluded from the analyses. Serum reactivity values from ELISA and flow cytometry assays were analyzed with and without log-transformation. The Student's t test was used when analyzed as continuous variables.
rVAR2-based pull downs of proteoglycans from sporadic BL cell lysates
The pull downs were performed as in Ref. 44 . In short, BLderived cells were washed in cold PBS and treated with cell lysis buffer (150 mM NaCl, 50 mM tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), 2.5 mM MgCl 2 , 1 mM ethylenediaminetetraacetic acid (EDTA), 1% 3-((3-cholamidopropyl) dimethylammonio)21-propanesulfonate (CHAPS) and protease and phosphatase inhibitor cocktails (Roche)). For the analysis of secreted proteoglycans, cells were grown for 3 days in complete media, which were collected for the analysis. Cell lysates of 10 3 10 6 cells or media were precleared for unspecific binding by incubation with MyOneC1 Streptavidin Dynabeads (Invitrogen) for 1 hr at 48C. Five micrograms of biotinylated rVAR2 was added to the sample preparation and incubated overnight at 48C, after which the rVAR2-bound lysate was incubated with the streptavidin-coated dynabeads for 1 hr at 48C. Following four gentle washes using a magnet, rVAR2-bound proteoglycans were eluded by boiling the samples in nonreducing LDS buffer (Invitrogen). The proteins were reduced in 1 mM 1,4-dithiothreitol (DTT) and alkylated with 5.5 mM iodoacetamide. The samples were run 1 cm into a Bis-Tris gel and stained with Coomassie Blue. The protein fractions were cut out of the gel, washed and in-gel digested with trypsin. The resulting peptides were captured and washed using a C18 resin in stage-tipping. The peptides were sequenced using a Fusion Orbitrap Mass Spectrometer. Sample analysis and hit verification were performed using the MaxQuant software. All samples were verified against control samples of cell lysates without rVAR2. For the Ingenuity Pathways Analysis (IPA), the verified hits were analyzed using the Ingenuity Pathways Analysis software (Qiagen) with focus on cellular function and disease.
Cytotoxicity BL-derived cells were cultured in a 96-well plate with 25,000 cells per well in 100 ll RPMI supplemented with 10% FBS. rVAR2 conjugated to the microtubule inhibitor (VDC) was prepared in RPMI supplemented with 10% FBS in threefold dilutions. Unconjugated cytotoxin 4 was included as a control. Furthermore, ofCS specificity of VDC and toxin were tested by CSA co-incubations. Twenty-five microliters of 5 times the dose response was spiked into each well in triplicate. Plates were incubated at 378C, 5% CO 2 for 72 hrs, following which viability was quantified by a 10 min CellTiterglo reagent incubation and SpectraMax measurement.
Results
Burkitt lymphoma displays oncofetal CS
To investigate whether BL tissue display ofCS, we examined 16 endemic BL tumor biopsies using immunohistochemistry. Binding of rVAR2 was detected in 62.5% (10/16) of the BL cores. Positive samples showed moderate-to-strong staining in the extracellular matrix of the lymphoma lesions while the staining of the BL cell membrane and cytoplasm was generally low (Fig. 1) . The same staining pattern was seen when rVAR2 binding was tested using immunofluorescence (Fig.  2) . To confirm the specificity of rVAR2 for ofCS, rVAR2 binding was outcompeted with soluble CSA. Additionally, a BL tumor biopsy was treated with ChABC before rVAR2 staining. ChABC treatment and CSA inhibition efficiently removed rVAR2 staining (Fig. 2) . Taken together, this illustrates that rVAR2 is binding specifically to ofCS in BL. The rVAR2 BL stainings are consistent with our previous observation that ofCS is often found as a part of the cancer-modified CSPGs in the tumor stroma. 16 The results indicate that BL tissue, if accessible, could in theory provide a binding niche for adhesion of VAR2CSA-expressing infected erythrocytes. Therefore, we proceeded to examine the BL tissue cores for the presence of P. falciparum-infected erythrocytes in the vascularized parts of the cancer tissue. None of the BL tissue cores, including five from subjects who were confirmed as malaria positive at the time of tissue sampling, showed sequestration of infected erythrocytes using H&E and Giemsa stains (data not shown). Thus, this study did not provide evidence for sequestration of infected erythrocytes within the BL tissue despite the presence of ofCS.
Anti-VAR2CSA IgG levels are slightly decreased in serum samples from Burkitt lymphoma patients
In general, children from malaria-endemic areas have low serum levels of anti-VAR2CSA IgG, as VAR2CSA-expressing parasites have no medium for sequestration and therefore are effectively cleared early in the infection. 34 In the case that VAR2CSA-expressing parasites can utilize BL tissue for sequestration in a similar way as the placenta during pregnancyassociated malaria infections, it would be expected that BL patients acquired an elevated IgG response to VAR2CSA.
To investigate this theory, we tested serum anti-VAR2CSA antibody levels in samples from Ghanaian BL patients and endemic controls (Supporting Information, Table 1 ). Two assays were employed. At first, we used ELISA to test the IgG response toward recombinant full-length VAR2CSA protein. The anti-VAR2CSA IgG serum levels were not higher in the BL patients; in fact, IgG reactivity towards immobilized full-length VAR2CSA was slightly but significantly lower in the BL patients than the controls (p 5 0.012) (Fig. 3A) . Furthermore, in the analysis of anti-VAR2CSA IgG levels by age, the BL cases showed consistently lower antibody means at all ages examined (Supporting Information, Fig. 2 ). To assure that this was not an observation solely related to the recombinant protein, we tested the IgG levels against native VAR2CSA expressed on P. falciparum-infected erythrocytes by flow cytometry. In flow cytometry, serum samples likewise showed a slightly decreased VAR2CSA-reactivity in the BL samples compared to serum from controls (p 5 0.02) (Fig. 3B) . The two analytical methods showed a significant positive correlation (r 5 0.29, p < 0.0001) using the Bonferonni-adjusted pairwise correlation. However, the effect size was small and there was considerable overlap between the groups. Control serum samples of Tanzanian children furthermore showed lower levels of anti-VAR2CSA IgG levels than what was found for the BL patients ( Supporting Information, Fig. 3) . Thus, the slight decrease in anti-VAR2CSA IgG levels for BL serum samples might not be sufficient to have an actual biological impact on malaria manifestations.
VAR2CSA binds Burkitt lymphoma cell lines
To test whether BL-derived cells display ofCS we tested eight cell lines, including three that were EBV-positive, for binding of rVAR2 in flow cytometry. All cell lines were bound by rVAR2 to some degree, however, the intensity of staining varied considerably (Fig. 4a) . rVAR2 did not bind to nonmalignant B-cells (data not shown). We found no correlation between rVAR2 staining intensity and EBV status of the cell lines. For example, the EBV-negative EW36 and EBVpositive KK124 cell lines both showed intense staining with rVAR2, while the EBV-positive LP120 and the EBV-negative cell lines CA46 and BML895 cell lines showed intermediate and low staining, respectively. We confirmed the specificity of rVAR2 binding to ofCS in a competitive assay by adding soluble CSA to the rVAR2-incubated cells (Fig. 4b) .
To further demonstrate the ofCS specificity of rVAR2 binding to BL-derived cell lines, four of the cell lines were stained with 200 nM rVAR2 in the presence of increasing amounts of CSA and HS. The data showed that coincubation of rVAR2 with soluble CSA inhibits the binding of rVAR2 to the cells, even at low concentrations. Contrary to this, HS did not compete for rVAR2 binding to ofCS even at 200 lg/ml (Figs. 5a-5e ). Pretreating the cells with ChAC efficiently removed binding of rVAR2 to the cells (Fig. 5e) . A domain of the VAR2CSA protein that is known to not to be involved in the binding of VAR2CSA to ofCS (rDBL4) was used as a protein control, and showed no binding to the cells (Fig. 5e) . Taken together, these data demonstrate that rVAR2 specifically binds to ofCS in the BL-derived cell lines.
The individual BL cell lines showed varying staining with rVAR2. To see if this difference was due to differences in the cells' overall CS content or an observable difference in CS structure, the 4 BL cell lines were subjected to CS structural analysis using AMAC labelling and HPLC. The cell lines all showed different CS concentrations and structure (Table 1) , however, there was no apparent link between this and the rVAR2 binding.
Finally, we showed that VAR2CSA-expressing infected erythrocytes bound to the BL-derived cell lines (Fig. 4c) , suggesting that the native VAR2CSA is capable of mediating infected erythrocytes binding to ofCS on BL cells.
rVAR2 binds to CSPGs displayed and secreted by the BLderived cancer cell lines
CSPGs are implicated in cancer through their involvement in proliferation, migration, apoptosis, adhesion and invasion. As CSPGs are also found in nonmalignant tissues, their oncogenic potential has been ascribed to a general upregulation as well as modifications of the CS structure. ofCS is a common modification on many proteoglycans in cancer. 16 To gain insight into which proteoglycans carry ofCS in BL, we performed rVAR2-based pull downs of CSPGs from the cell lysates of four BL cell lines as well as from their conditioned media. The samples were incubated with biotinylated rVAR2, potential rVAR2-binding proteins were isolated using streptavidin-coated magnetic beads and identified by mass spectrometry ( Table 2 ). All cell lines expressed multiple rVAR2-bound CSPGs in line with a previous study that showed that malignant lymphoid cells in general express more types of cell-associated proteoglycans than normal lymphocytes. 45 Among the hits were several well-known cancer- associated CSPGs such as CD44, CD47, CD74 and APP. [46] [47] [48] [49] [50] Furthermore, several VAR2-bound CSPGs including serglycin and biglycan were identified in the media of the cell cultures.
The heterogeneity between the cell lines in what proteoglycans are modified with an ofCS chain could be the reason for the differences in the level of rVAR2 binding to the cell lines ( Fig. 4 ) As we have recently described, rVAR2 ofCS-specific pull down from cell lysates revealed a number of proteins that included ofCS substituted CSPGs as well as several known CSPG interaction partners, such as integrins. 44 To attempt to get an overview over the connection between all the hits as well as how they relate to cellular functions and disease processes in BL, the identified hits were subjected to ingenuity pathway analysis (IPA). This shows an involvement of ofCS in several immune pathways, and in processes related to the development of immunological diseases ( Supporting Information, Fig. 4 ).
Toxin-conjugated rVAR2 kills BL-derived cell lines
The high degree of rVAR2 staining in many BL tissues as well as the expression of multiple rVAR2-defined CSPGs on each cell line indicate that rVAR2 can be used to target a broad panel of BL and that binding would not be confined to the expression of a single tumor marker. We have recently shown that rVAR2 coupled to a cytotoxic microtubule inhibitor was effective in specific killing of a number of cancer cells in vitro and in vivo. 16 Thus, we tested whether the rVAR2 drug conjugate (VDC) could mediate killing of BL-derived cell lines in vitro. VDC effectively killed the BL-derived cell lines with EC50 values of 0.4 nM for EW36, 1.9 nM for KK124, 2.2 nM for SHO and 7.3 nM for JLP119 (Fig. 6) . Killing efficacy aligned with the flow cytometry staining intensity of cell lines, where EW36 and KK124 also displayed the strongest rVAR2 binding. The effect of the rVAR2-induced cytotoxicity must however also be expected to depend on the individual CSPGs targeted on the cell lines. The rVAR2-induced cytotoxicity was shown to be ofCS specific as the cytotoxicity could be inhibited by a coincubation with soluble CSA. These data highlight the potential of using rVAR2 for therapeutic targeting of BL.
Discussion
Although the link between P. falciparum and BL was made >50 years ago, this is the first study to explore the expression of malaria-associated receptors in BL and whether such expression can be exploited to target BL therapy. Taken together, our results suggest that studies of evolutionarily refined pathogen malaria proteins in BL may represent novel opportunities for discovery of ways to target BL therapy. When we set out to explore the interplay between malaria infections and cancer, we initially hypothesized that a vascularized tumor could possibly act like a placenta by creating a niche for ofCS binding of VAR2CSA-expressing parasites. Experiments confirmed the presence of ofCS in many BL tissues and we showed that rVAR2 binds BL-derived cell lines. Furthermore, we showed that infected erythrocytes expressing VAR2CSA are capable of binding to BL cell lines. However, when we tested the theoretical possibility that VAR2CSA-presenting infected erythrocytes adhere to the vascularized parts of the BL in vivo, we did not find any indications of parasite sequestration in BL tissue from malaria-infected patients. While the small sample size of our study should be considered, one explanation could be that the ofCS expressing compartments of BL are inaccessible to the infected erythrocytes due to the high rate of BL cell proliferation and relatively low vascularity of BL with tendency to early necrosis. An additional explanation could be a difference in the flow rate of the peripheral vascularized tissues compared to the placenta. Furthermore, the placenta is a partly immune restricted region, which might contribute to pregnancyassociated malaria.
Had VAR2CSA-expressing infected erythrocytes been adhering in the BL tissue, we would expect higher levels of anti-VAR2CSA antibodies in the BL patients as is seen in patients suffering from pregnancy-associated malaria. Our results are internally consistent as serum samples of BL patients showed slightly reduced anti-VAR2CSA IgG levels compared to the endemic controls. In general, the anti-VAR2CSA levels were much lower in the BL patients as compared to women who have been exposed to pregnancyassociated malaria infection. As the BL ECM shows abundant ofCS, it is possible that the tumor tissues leak or actively secret ofCS, which could coat circulating VAR2CSA-expressing infected erythrocytes and inhibit their sequestration, thereby promoting more rapid clearance from circulation by macrophages and the spleen. If so, secreted ofCS could hinder tissue sequestration and reduce the low-level boosting of anti-VAR2CSA antibodies. In line with this, we showed that BL-derived cell lines secrete ofCS carrying CSPGs such as serglycin and biglycan, which could be bound by rVAR2. Serglycin is one of the dominant proteoglycans of hematopoietic cells and was accordingly identified by rVAR2 on JLP119 and KK124 as well as secreted from EW36. Furthermore, rVAR2-based pull downs identified biglycan in the media from all the four tested cell lines. Biglycan has been found to be a serum biomarker elevated in esophageal adenocarcinoma, but to our knowledge, the protein has not yet been explored in BL. 51 Combined, the lack of evidence for binding of infected erythrocytes in BL tissue and our serological data do not support the notion that cancer tissue provides a niche for binding of VAR2CSA expressing parasites in children with BL. However, we were only able to investigate a limited number of BL needle biopsies from patients with a positive malaria blood slide. Thus, we cannot reject that sequestration might occur in some patients. Furthermore, we cannot rule out that there are submicroscopic infections of limited clinical and immunological impact in BL tissues.
Inaccessibility to the BL tissue or secretion of ofCS into the blood stream could potentially impair the manifestation of low levels of VAR2CSA-expressing infected erythrocytes. However, it is possible that the rVAR2 protein could reach ofCS in the tumor and thus be used to deliver a toxic payload to BL patients. Though toxic chemotherapy of BL has been successful, BL remains a serious cause of cancer deaths in low-income countries. Therefore, alternative targeting strategies for BL should be explored. The abundant presence of ofCS in BL tissue, combined with the previously shown absence of ofCS in nonmalignant tissue, 16 suggested that rVAR2 can target BL cells and that a rVAR2 drug conjugate (VDC) could be used in the treatment of BL. Furthermore, our data indicate that VDC could potentially be used to target a broader panel of BL malignancies, as it would not be restricted to the expression of a single tumor target. We found rVAR2 to bind to multiple surface-exposed CSPGs including CD47, CD74 and APP, which all have an oncogenic role. Elevated levels of CD47 have been shown to be important for avoiding macrophage clearance and promoting dissemination of non-Hodgkin lymphoma including BL. 48 Likewise, CD74 plays an important role for malignant B-cell proliferation and survival. 52 Studies in BL xenografted mice have indicated that anti-CD74 antibodies antagonistic or toxin-coupled can be applied for treatment of BL. 49, 53 Finally, APP is highly expressed in EBV-negative BL and seems to be implicated in the rapid proliferation rate of these cells. 50 The specific targeting of CSPGs implicated in the oncogenic potential of BL cells was supported by in vitro cytotoxicity. VDC induced BL cytotoxicity with low EC50 values, demonstrating its effective killing of BL cells in vitro.
In summary, we have shown that rVAR2 binds to BLderived cell lines as well as patient tissue and that the VDC facilitates potent killing of BL cells in vitro. There is a certain irony in the fact that a protein derived from a pathogen such as malaria long suspected to play a role in the pathogenesis of eBL can be modified and used as a potential therapeutic agent against the malignancy.
